Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration
2019-03-06
FDA-2018-D-1398
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration March 2019
Not for implementation. Contains non-binding recommendations.
March 2019
The FDA Food Safety Modernization Act (FSMA) added to the Federal Food, Drug, and Cosmetic Act (FD&C Act) several new sections that reference intentional adulteration. For example, section 418 of the FD&C Act (21 U.S.C. 350g) addresses intentional adulteration in the context of facilities that manufacture, process, pack, or hold food, and that are required to register under section 415 (21 U.S.C. 350d). Section 420 of the FD&C Act (21 U.S.C. 350i) addresses intentional adulteration in the context of high-risk foods and exempts farms except for farms that produce milk [2].
We implemented these intentional adulteration provisions through a rule entitled “Mitigation Strategies to Protect Food Against Intentional Adulteration” (IA rule).We published the final rule in the Federal Register of May 27, 2016. (81 FR 34166).
The rule, which includes the requirements for food defense measures against intentional adulteration, and related requirements, can be found in 21 CFR part 121, as shown in Table 1.
Table 1. Subparts Established in 21 CFR Part 121
| Subpart | Title |
|---|---|
| A | General Provisions |
| B | Reserved |
| C | Food Defense Measures |
| D | Requirements Applying to Records That Must Be Established and Maintained |
| E | Compliance |
As shown in Table 2 below, the amount of time we are allowing you to comply with the IA rule depends on your particular business.
Table 2. Compliance Dates for IA Rule Based on Size of Business
| Size of Business | Compliance Date |
|---|---|
| Very Small | July 26, 2021 |
| Small | July 27, 2020 |
| Other businesses that do not qualify for exemptions | July 26, 2019 |
The IA rule applies to the owner, operator, or agent in charge of a domestic or foreign food facility that manufactures/processes, packs, or holds food for consumption in the United States and is required to register under section 415 of the FD&C Act, unless one of the exemptions provided in 21 CFR 121.5 applies. (21 CFR 121.1).
Acts of intentional adulteration may take several forms: acts intended to cause wide scale public health harm, such as acts of terrorism focused on the food supply; acts of disgruntled employees, consumers, or competitors; and economically motivated adulteration (EMA). Acts intended to cause wide scale public health harm are associated with intent to cause significant human morbidity and mortality. The other forms are typically not intended to cause wide scale public health harm, although some public health harm may occur because of the adulteration. For example, acts of disgruntled employees, consumers, and competitors are generally intended to attack the reputation of a company, and EMA is intended to obtain economic gain. In the spectrum of risk associated with intentional adulteration of food, attacks intended to cause wide scale public health harm to humans are ranked as the highest risk. Therefore, the IA rule is focused on addressing those acts and not acts of disgruntled employees, consumers, or competitors, or acts of EMA [3].
This document is directed to those persons who are subject to the Intentional Adulteration (IA) requirements of 21 CFR part 121 (you). Identifying significant vulnerabilities at your facility and implementing mitigation strategies and mitigation strategy management components enables you to apply a proactive and systematic approach to your food defense program to protect your food from intentional adulteration intended to cause wide scale public health harm.
This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.
Related Information
- Supplemental Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration
- FSMA Final Rule for Mitigation Strategies to Protect Food Against Intentional Adulteration
- Constituent Update: FDA Releases Third Installment of the Draft Guidance for the Intentional Adulteration rule (02/13/2020)
- Constituent Update: FDA Extends Comment Period for Third Installment of the Draft Guidance for the Intentional Adulteration Rule (05/27/2020)
- Protecting the Food Supply from Intentional Adulteration, Such as Acts of Terrorism
See additional information on commenting: Stakeholders Will Be Able to Comment on First Two Volumes of the Intentional Adulteration Rule Draft Guidance Together
[1] This guidance has been prepared by the Office of Analytics and Outreach, Food Defense and Emergency Coordination Staff, in the Center for Food Safety and Applied Nutrition at the U.S. Food and Drug Administration.
[2] The IA rule did not include any requirements for farms that produce milk. As such, farms that produce milk are not covered under this draft guidance.
[3] As we noted in the final rule, the protections required by the rule will help minimize the likelihood of success of a disgruntled employee, consumer, or competitor who attempts an act of intentional adulteration at an actionable process step—even if that act is not intended to cause wide scale public health harm. (81 FR at 34183).
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2018-D-1398.
最新政策法规资讯
-
摩熵医药2026-06-17
-
摩熵医药2026-06-09
-
赛柏蓝2026-06-01
-
深蓝观2026-05-22
-
赛柏蓝2026-04-24
-
摩熵医械2026-01-28
-
摩熵医械2026-01-13
-
摩熵医械2025-12-19
-
赛柏蓝2025-12-12
-
摩熵医械2025-11-28
热门政策标签
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-10-14
-
2026-10-14
-
摩熵咨询 35 78
-
摩熵咨询 28 65
-
颁布机构:国家市场监督管理总局 2026-09-30
-
颁布机构:国家市场监督管理总局 2026-09-29
最新指导原则
-
国家药监局器审中心关于发布<人表皮生长因子受体2基因扩增检测试剂(荧光原位杂交法)注册审查指导原则(2026年修订版)>等2项注册审查指导原则的通告(2026年第28号)
2026-10-13
-
questions and answers on biosimilar development and the bpci act: guidance for industry(生物类似药开发与<生物制品价格竞争与创新法案>问答:行业指南)
2026-10-09
-
postapproval manufacturing changes to biosimilar and interchangeable biosimilar products: questions and answers(生物类似药和可互换生物类似药产品的批准后生产变更:问答)
2026-10-09
-
国家药监局器审中心关于发布有源植入式医疗器械电池注册审查指导原则的通告(2026年第27号)
2026-10-08
-
国家药监局器审中心关于发布腹腔内窥镜手术系统注册审查指导原则 第5部分:患者模型试验研究>的通告(2026年第26号)
2026-09-28
-
国家药监局综合司公开征求<医疗器械生产质量管理规范无菌医疗器械检查指导原则(征求意见稿)>等意见
2026-09-24
-
关于公开征求ich<e14/s7b:问答:致qt/qtc 间期延长及潜在致心律失常作用的临床和非临床评价问答>指导原则问答文件实施建议和中文翻译稿意见的通知
2026-09-24
-
国家药监局药审中心关于发布<药物临床试验计算机化系统和电子数据指导原则>的通告
2026-09-22
-
国家药监局药审中心关于发布<化学仿制药滴眼剂研究技术指导原则>和<化学仿制药特殊滴眼剂研究技术指导原则>的通告
2026-09-02
-
determining whether to submit an anda or a 505(b)(2) application(确定是提交仿制药申请(anda)还是505(b)(2)申请)
2026-08-17
-
cvm gfi #260 - type vii veterinary master file for research and development and risk reviews(cvm行业指南第260号——用于研发与风险审查的vii型兽药主文件)
2026-08-14
-
container closure systems for human drugs and biological products(人用药品和生物制品的容器密闭系统)
2026-08-13
-
formal meetings between the fda and sponsors or applicants of pdufa products(关于fda与处方药使用者付费法案(pdufa)产品申办方或申请人之间正式会议的指南)
2026-08-12
-
国家卫生健康委办公厅关于印发医疗机构卒中中心建设与管理指导原则(2026年版)的通知
2026-07-28
-
hemodialysis blood tubing sets - premarket notification (510(k)) submissions: guidance for industry and food and drug administration staff(血液透析血液管路套装 - 上市前通知(510(k))申报资料:行业和食品药品监督管理局工作人员指南)
2026-07-23
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-10-15
-
2026-10-15
-
2026-10-15
-
摩熵咨询 33 34
-
摩熵咨询 20 8
-
摩熵咨询 20 12
-
颁布机构:国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构:国家药品监督管理局 2026-09-10
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
同部门最新指导原则
-
Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics
2024-11-15
-
Guidance for Industry: FDA's Voluntary Qualified Importer Program
2024-11-14
-
CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products – Decomposition and Histamine (CPG 7108.24)
2024-11-01
-
Study Data Technical Conformance Guide - Technical Specifications Document
2024-10-31
-
M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms
2024-10-30
-
CVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients
2024-10-24
-
Guidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination
2024-10-22
-
Drug Interaction Information in Human Prescription Drug and Biological Product Labeling
2024-10-21
-
Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA
2024-10-17
-
Postoperative Nausea and Vomiting: Developing Drugs for Prevention
2024-10-17
-
Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method
2024-10-17
-
Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development: Guidance for Industry
2024-10-17
-
Core Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry
2024-10-17
-
Requests for Reconsideration at the Division Level Under GDUFA
2024-10-16
-
CVM GFI #284 Using Relative Supersaturation to Support “Urinary Tract Health” Claims for Adult Maintenance Cat Food
2024-10-15
同地域最新指导原则
-
questions and answers on biosimilar development and the bpci act: guidance for industry(生物类似药开发与<生物制品价格竞争与创新法案>问答:行业指南)
2026-10-09
-
postapproval manufacturing changes to biosimilar and interchangeable biosimilar products: questions and answers(生物类似药和可互换生物类似药产品的批准后生产变更:问答)
2026-10-09
-
determining whether to submit an anda or a 505(b)(2) application(确定是提交仿制药申请(anda)还是505(b)(2)申请)
2026-08-17
-
cvm gfi #260 - type vii veterinary master file for research and development and risk reviews(cvm行业指南第260号——用于研发与风险审查的vii型兽药主文件)
2026-08-14
-
container closure systems for human drugs and biological products(人用药品和生物制品的容器密闭系统)
2026-08-13
-
formal meetings between the fda and sponsors or applicants of pdufa products(关于fda与处方药使用者付费法案(pdufa)产品申办方或申请人之间正式会议的指南)
2026-08-12
-
hemodialysis blood tubing sets - premarket notification (510(k)) submissions: guidance for industry and food and drug administration staff(血液透析血液管路套装 - 上市前通知(510(k))申报资料:行业和食品药品监督管理局工作人员指南)
2026-07-23
-
opioid analgesic drugs: considerations for benefit-risk assessment framework(阿片类镇痛药:效益-风险评估框架的考量)
2026-05-13
-
development of non-opioid analgesics for acute pain(急性疼痛的非阿片类镇痛药开发)
2026-05-13
-
development of local anesthetic drug products with prolonged duration of effect(延长作用时间的局部麻醉药品的开发)
2026-05-13
-
stimulant use disorders: developing drugs for treatment(兴奋剂使用障碍:治疗药物的开发)
2026-05-13
-
development of non-opioid analgesics for chronic pain(慢性疼痛非阿片类镇痛药的开发)
2026-05-13
-
pulmonary tuberculosis: developing drugs for treatment(肺结核:治疗药物的开发)
2026-05-08
-
clostridioides difficile infection: developing drugs for treatment, reduction of recurrence, and prevention(艰难梭菌感染:用于治疗、减少复发及预防的药物开发)
2026-05-08
-
enforcement priorities for certain new tobacco products marketed without premarket authorization(未经上市前授权销售的某些新烟草产品的执法重点)
2026-05-08

